Susquehanna International Group, LLP Acumen Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.22 - $3.54 $232,656 - $370,992	-104,800 Reduced 65.66%	54,800 $135,000
Q2 2024 Aug 15, 2024	SELL	$2.14 - $4.01 $175,480 - $328,820	-82,000 Reduced 33.94%	159,600 $386,000
Q1 2024 May 07, 2024	BUY	$2.97 - $4.64 $245,619 - $383,728	82,700 Added 52.05%	241,600 $978,000
Q4 2023 Feb 14, 2024	BUY	$1.86 - $4.48 $98,766 - $237,888	53,100 Added 50.19%	158,900 $610,000
Q3 2023 Nov 14, 2023	SELL	$4.15 - $9.72 $146,495 - $343,116	-35,300 Reduced 25.02%	105,800 $439,000
Q2 2023 Aug 11, 2023	BUY	$3.59 - $6.59 $354,692 - $651,092	98,800 Added 233.57%	141,100 $678,000
Q1 2023 May 16, 2023	BUY	$3.75 - $6.65 $26,625 - $47,215	7,100 Added 20.17%	42,300 $171,000
Q4 2022 Feb 14, 2023	SELL	$4.81 - $10.17 $409,811 - $866,484	-85,200 Reduced 70.76%	35,200 $190,000
Q3 2022 Nov 14, 2022	BUY	$4.44 - $10.48 $534,576 - $1.26 Million	120,400 New	120,400 $1.21 Million

41.8M

57.7K

749K

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $72.5M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.